secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adaptimmune Therapeutics PLC (—)
CIK:        0001621227
Form:       8-K
Filed at:   2025-04-14T23:59:59+00:00
Accession:  0001558370-25-004768
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adaptimmune extends CFO Gavin Wood's departure to August 31, 2025
-----------------------------------------------------------------

- Original termination date of May 31, 2025 changed to August 31, 2025 by reason of redundancy.
- Severance includes 12 months base salary, discretionary pro-rata bonus for 2025, and healthcare benefits for 12 months.
- Share options continue vesting until August 31, 2025; vested options exercisable for 12 months thereafter.
- All other provisions of the original letter agreement and service agreement obligations survive unchanged.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1621227/000155837025004768/0001558370-25-004768-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1621227/000155837025004768/adap-20250414x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-004768

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer